.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G02B_ContraceptivesForTopicalUse.G02BB01_VaginalRingWithProgestogenAndEst.VaginalRingWithProgestogenAndEst .Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G02B_ContraceptivesForTopicalUse.G02BB01_VaginalRingWithProgestogenAndEst.VaginalRingWithProgestogenAndEst| name: | VaginalRingWithProgestogenAndEstrogen |
| ATC code: | G02BB01 | route: | vaginal |
| n-compartments | 1 |
The vaginal ring containing progestogen and estrogen is a contraceptive device designed for intravaginal administration delivering a combination of an estrogen (usually ethinylestradiol) and a progestogen (such as etonogestrel). It provides effective reversible contraception and is approved for use by women of reproductive age.
Pharmacokinetic parameters estimated for a typical healthy adult female user, as reported for the etonogestrel/ethinylestradiol vaginal ring (e.g., NuvaRing).
Nelson, AL (2019). Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method. Expert review of clinical pharmacology 12(10) 953–963. DOI:10.1080/17512433.2019.1669448 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31526281
Thakur, K, et al., & Polak, S (2024). Development and verification of mechanistic vaginal absorption and metabolism model to predict systemic exposure after vaginal ring and gel application. British journal of clinical pharmacology 90(6) 1428–1449. DOI:10.1111/bcp.16029 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38450818
Shaaban, MM (1991). Contraception with progestogens and progesterone during lactation. The Journal of steroid biochemistry and molecular biology 40(4-6) 705–710. DOI:10.1016/0960-0760(91)90294-f PUBMED:https://pubmed.ncbi.nlm.nih.gov/1835650